In-house members
15
Total footprint
30,000sq ft
Our Old Market incubator hosts growing Deep Tech companies that have moved beyond proof of concept and are scaling their teams, typically 20–30 people strong.
This site serves as the main event venue of our Bristol campus — featuring the 1023 Bar, our community’s main stage for events and a gathering spot for informal meetups every Thursday.
Old Market members are breaking new ground in several science and engineering fields — from advanced sustainable materials to vaccine platforms and stem cell therapeutics.
With 30,000 sq ft of laboratory, office and meeting space, our Old Market incubator is a supportive, well-connected hub for growing Deep Tech companies.
This location also features a large event space, shared social spaces, and our favourite addition — the 1023 Bar, open every Thursday for the community.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.





If you are looking for private lab and office space, get in touch to enquire about our current availability at Old Market or explore OMX, our third Bristol incubator, set to open in 2026.



Travel between locations is measured in walking distance
Midland Rd & St Philips Rd
0.5 miles / 11 min
0.7 miles / 15 min

Fine Agrochemicals is enhancing crop quality for fruit and flower growers in agricultural, ornamental and landscape markets using its plant growth regulator (PGR) technology. Its PGR products, made using naturally occurring molecules through fermentation and combined with chemically synthesised compounds, help stimulate plant cells to enhance nutrient levels and targeted growth for improved crop outputs.

Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.

CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.




Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.

Carbometrics is striving to improve diabetes patient care by enhancing technology for continuous glucose monitoring. The team aims to pave the way for a new class of highly-accurate sensors with its groundbreaking synthetic molecule that is both chemically stable and able to bind to glucose in the blood. This follows on from the work of exited startup Ziylo Ltd, which was Science Creates’ very first resident and acquired by Novo Nordisk in 2018.

Uplift360 is developing chemical-based regeneration technologies to recover and reuse critical industrial materials such as carbon fibre and aramid. Its vision is to lead the way in circular economy innovation, creating a future where advanced materials are never wasted. Backed by the UK Defence and Security Accelerator (DASA), Luxembourg Government Directorate of Defence and Innovate UK, it enables circular and secure supply chains for high-performance sectors.




Transdermal Diagnostics is pioneering the development of bio-wearables that enhance the prevention, diagnosis and management of chronic conditions like diabetes. Its unique sensing technology aims to create the world’s first needle-free continuous monitor for glucose and other health biomarkers. By analysing hair follicles, the adhesive skin patch and transmitter wirelessly communicate information straight to a smartphone app, facilitating a transformative shift in patient care and quality of life for those with diabetes.

Reach Industries is optimising lab and scientist efficiency with its Lumi™ visual intelligence platform. By automating data capture and analysis for experiments, observations and complex scientific workflows, the platform functions as a streamlined operating system that is accelerating R&D, improving compliance and increasing reproducibility.

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.


